Time for the dawn of multimodal therapies and the dusk for mono‐therapeutic trials for cholestatic liver diseases?

Wagner, Martin; Fickert, Peter

doi:10.1111/liv.13744

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this review we have outlined several molecules which can play a role in the therapeutic armamentarium of PBC and PSC. Although, we agree that cholestatic liver diseases will not be properly treated until a multimodal approach is employed [125]. Pathogenesis of PBC and PSC include dysregulation of the immune system, inflammation, bile acid toxicity and fibrogenesis, while current treatment strategies are limited to only one or two of these components.…”

Section: Discussionmentioning

confidence: 83%

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

Gerussi

D’Amato

Cristoferi

et al. 2020

Annals of Hepatology

View full text Add to dashboard Cite

Primary biliary cholangitis and primary sclerosing cholangitis are rare diseases affecting the bile ducts and the liver. The limited knowledge of their pathogenesis leads to limited therapeutic options. Nevertheless, the landscape of novel therapies for these cholangiopathies is now rapidly changing, providing new treatment opportunities for patients and clinicians involved in their care. The aim of this review is to summarize the evidence of novel molecules under investigation for primary biliary cholangitis and primary sclerosing cholangitis and to discuss how they can potentially change current treatment paradigms.

show abstract

Section: Discussionmentioning

confidence: 83%

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

Gerussi

D’Amato

Cristoferi

et al. 2020

Annals of Hepatology

View full text Add to dashboard Cite

show abstract

“…Then, we need to implement algorithms to proficiently integrate these big data to cluster patients across different phenotypes and trajectories of the disease (105,106); for this, the collaboration with data science professionals and experts in artificial intelligence will be fundamental (107,108). The last part of this process will be to put in practice clinical trials with different, multimodal treatment strategies (109).…”

Section: Discussionmentioning

confidence: 99%

New Therapeutic Targets in Autoimmune Cholangiopathies

et al. 2020

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are autoimmune cholangiopathies characterized by limited treatment options. A more accurate understanding of the several pathways involved in these diseases has fostered the development of novel and promising targeted drugs. For PBC, the characterization of the role of farnesoid X receptor (FXR) and perixosome-proliferator activated receptor (PPAR) has paved the way to several clinical trials including different molecules with choleretic and antinflammatory action. Conversely, different pathogenetic models have been proposed in PSC such as the "leaky gut" hypothesis, a dysbiotic microbiota or a defect in mechanisms protecting against bile acid toxicity. Along these theories, new treatment approaches have been developed, ranging from drugs interfering with trafficking of lymphocytes from the gut to the liver, fecal microbiota transplantation or new biliary acids with possible immunomodulatory potential. Finally, for both diseases, antifibrotic agents are under investigation. In this review, we will illustrate current understanding of molecular mechanisms in PBC and PSC, focusing on actionable biological pathways for which novel treatments are being developed.

show abstract

Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy

Panzitt¹,

Fickert²,

Wagner³

2021

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

View full text Add to dashboard Cite

Time for the dawn of multimodal therapies and the dusk for mono‐therapeutic trials for cholestatic liver diseases?

Abstract: See Article on Page 1128

Cited by 5 publications

References 15 publications

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

New Therapeutic Targets in Autoimmune Cholangiopathies

Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy

Contact Info

Product

Resources

About